Features Partner Sites Information LinkXpress
Sign In
Demo Company

Ingenuity Systems Acquired by Qiagen, Adding Analysis, Interpretation of Complex Biologic Data Technology

By BiotechDaily International staff writers
Posted on 07 May 2013
Print article
Qiagen NV (Hilden, Germany) has acquired Ingenuity Systems, Inc. (Redwood City, CA, USA), a leading provider of biomedical software that effectively analyzes and interprets the biologic meaning of genomic data. Ingenuity has created a curated knowledge system of biomedical data and analysis solutions for the investigation, interpretation, and analysis of complex biologic systems.

New developments such as next-generation sequencing (NGS) are now generating more data in only one year than was generated in all prior history, making the analysis and interpretation of this wide-ranging and very complex biologic data a critical success factor.

At the core of Ingenuity’s product range is the Ingenuity Knowledge Base, a 14-year endeavor to effectively and manually curate, model, and computationally structure the immense amount of biomedical literature, including genomic variations associated with human disease and thousands of disease models. The Ingenuity Knowledge Base and software applications enable users to accurately interpret the significance of increasingly large amounts of biologic data to better direct research and medical treatment decisions.

Ingenuity’s Knowledge Base is constructed on algorithms that pair all human gene variants with biologic interpretations based on known outcomes and discoveries. These pairings are gathered and reviewed by specialists (curated) in a standardized way from a wide range of sources including clinical and scientific publications with the support of advanced technology and refined processes. This process and the associated learning algorithms translate sourced data into interoperable and linkable collections of relevant information.

The Ingenuity product range includes the Ingenuity pathways analysis (IPA) standard web-based software application, which enables researchers to model, analyze, and determine the complex biologic systems at the core of life sciences research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports data analysis and interpretation from all high-throughput analysis platforms and it is used in virtually all areas of drug discovery and development from target identification and validation to predictive toxicology, biomarkers, and pharmacogenomics.

Ingenuity variant analysis is a web-based NGS data analysis application that solves a vital requirement for researchers trying to rapidly identify relevant causal variants in human diseases in a matter of hours. It enables customers to rapidly identify and prioritize variants by drilling down to a small, targeted subset of compelling variants based upon published biologic evidence and their own knowledge of disease biology. Users can also probe variants from multiple biologic standpoints, examine different biologic theories, and identify the most promising variants for follow-up analysis.

Up to now, thousands of users from leading institutions around the world have already uploaded genomic data using Ingenuity variant analysis, which has been used to analyze more than 45,000 biologic samples. In February 2013, Ingenuity had passed an audit under the US Health Insurance Portability and Accountability Act (HIPAA) and complies with the US-EU Safe Harbor framework.

Ingenuity will substantially expand and strengthen Qiagen’s own curated database, which is embedded in wet lab assays and marketed through Qiagen’s GeneGlobe content portal. GeneGlobe offers hundreds of assay panels for polymerase chain reaction (PCR) and NGS as well as more than 60,000 fully annotated molecular assays for the most sought-after diseases and pathways, curated from the biomedical literature.

Related Links:

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.